Clinical trials: Stage I Cervical Cancer
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
This phase I clinical trial studies the side effects and best dose of veliparib when given together with paclitaxel and cisplatin and to see how well they work in treating patients with cervical cancer that has spread to other…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma
- Trial name
- NCT01281852
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 25 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Radiation Toxicity
Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00012012
- Testing
- Amifostine trihydrate, Cisplatin, Intracavitary brachytherapy
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Radiation Therapy Oncology Group
Malignant Female Reproductive System Neoplasm, Stage I Cervical Cancer AJCC v8
Sexual Health Counseling Intervention During Radiation Therapy in Improving Quality of Life for Women With Gynecologic Cancer
This phase I trial studies a sexual health counseling intervention during radiation therapy in improving quality of life for women with gynecologic cancer.
- Conditions
- Malignant Female Reproductive System Neoplasm, Stage I Cervical Cancer AJCC v8, Stage I Uterine Corpus Cancer AJCC v8, Stage I Vaginal Cancer AJCC v8
- Trial name
- NCT04269837
- Testing
- Counseling, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Malignant Neoplasm of Breast, CNS Malignancy
Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors
This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously…
- Conditions
- Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified
- Trial name
- NCT01639911
- Testing
- Alisertib, Pazopanib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Illinois at Chicago
Esophageal Cancer
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer
The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides URLC10, TTK, and KOC1, emulsified with Montanide ISA 51.
- Trial name
- NCT00681330
- Testing
- URC10, TTK, KOC1
- Where
- Japan
- Volunteers
- 14 people
- Sponsor
- Tokyo University
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
This phase I trial is studying the side effects and best way to give radiation therapy when given together with topotecan and cisplatin in treating patients with locally advanced cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer
- Trial name
- NCT00054444
- Testing
- Topotecan Hydrochloride Liposomes, 3-Dimensional Conformal Radiation Therapy, Cisplatin
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer.
- Trial name
- NCT04683653
- Testing
- Hypofractionated Radiation, Clinical Follow-Up and Assessments
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Chicago
Xerostomia Due to Radiotherapy, Hyposalivation
Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth
An investigator-initiated, non-randomized, open label study to investigate the safety, feasibility and tolerability of intraglandular injection of allogeneic mesenchymal stem/stromal cells (MSCs) into the submandibular and…
- Conditions
- Xerostomia Due to Radiotherapy, Hyposalivation, Xerostomia, Oropharynx Cancer
- Trial name
- MESRIX-SAFETY (NCT03874572)
- Testing
- Allogeneic adipose derived stem/stromal cells
- Where
- 2 sites in Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Head and Neck Cancer
DNA Analysis of Tissue Samples From Patients With Head and Neck Cancer
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00898664
- Testing
- cytogenetic analysis, gene expression analysis, mutation analysis
- Volunteers
- 74 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cervical Cancer, Genital Wart
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45…
- Conditions
- Cervical Cancer, Genital Wart, CIN1, CIN2
- Trial name
- NCT05584332
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- China
- Volunteers
- 3,131 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Solid Tumor, Non-Small Cell Lung Cancer
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Colorectal Cancer
- Trial name
- NCT04930432
- Testing
- MCLA-129
- Where
- 87 sites in China
- Volunteers
- 400 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Head and Neck Cancer
Panitumumab IRDye800 Optical Imaging Study
Phase I trial to evaluate the safety of escalating dose levels of conjugated panitumumab-IRDye800 in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent.
- Trial name
- NCT02415881
- Testing
- Panitumumab IRDye 800, da Vinci Firefly, IMAGE1 + ICG Hopkins telescope and/or VITOM
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Eben Rosenthal
Head and Neck Cancer, Lung Cancer
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
RATIONALE: Fluorescent bronchoscopy, when used in combination with conventional white light bronchoscopy, may improve the ability to detect early lung cancer.
- Trial name
- NCT00019201
- Testing
- cytology specimen collection procedure, immunohistochemistry staining method, sputum cytology
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Head and Neck Cancer
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00083057
- Testing
- gefitinib, paclitaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Stage I Breast Cancer, Stage I Cervical Cancer
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
This pilot clinical trial studies how well the Carevive Survivor Care Planning System works in improving quality of life in breast cancer survivors.
- Conditions
- Stage I Breast Cancer, Stage I Cervical Cancer, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer
- Trial name
- NCT03198286
- Testing
- Informational Intervention
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Esophageal Cancer
Trial of Docetaxel, Cisplatin, Fluorouracil (5-FU) for Unresectable Advanced Esophageal Squamous Cell Carcinoma (ESCC)
This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and 5-fluorouracil (DCF) in unresectable…
- Trial name
- NCT00915850
- Testing
- DCF
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Wakayama Medical University
Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment…
- Conditions
- Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT02381561
- Testing
- Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00452920
- Testing
- docetaxel, cesium Cs 137, radiation therapy
- Where
- United States
- Sponsor
- University of Miami
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer